• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Technology Events 2023-2024
  • Sponsored Post
    • Make a Contribution
  • Technology Markets
    • Venture Capital
  • About
  • Contact

Coronavirus (COVID-19) Update: Serological Test Validation and Education Efforts

April 18, 2020 By admin Leave a Comment

The following is attributed to Commissioner of Food and Drugs – Food and Drug Administration, Stephen M. Hahn, M.D.

Every step we have taken as part of our approach to COVID-19 testing has been a careful balancing of risks and benefits in order to meet the urgent public health needs as we combat this new pathogen. We have moved quickly and thoughtfully, and we are continuing to learn and adapt based on the real-world experience and data we’re seeing. In the meantime, frontline health care workers who are making life-and-death decisions every day in their fight against this novel coronavirus need to have all the information possible to make educated decisions about which test to use to help identify individuals who have developed an immune response to the virus. We are committed to providing as up-to-date information as possible to support their heroic efforts.

As the country starts to see positive signs that the mitigation efforts, like stay-at-home orders and social distancing, are working in our fight against the COVID-19 pandemic, the question of when we can return to work and resume our normal activities is one of the most critical issues facing our nation. Antibody tests – also known as serological tests – may have the potential to play a role in this complex calculation. Results from these tests can help identify who has been infected and developed antibodies that may protect from future infection as well as identify those still at risk. Results can also help inform who may qualify to donate blood that can be used to manufacture convalescent plasma, an investigational product for use with those who are seriously ill from COVID-19.

Today, given the active dialogue about serological tests that are currently on the market, and their significance in the nation’s response efforts, we’d like to provide further details about our thinking on these tests and our approach to making accurate and reliable serology tests widely available, while also protecting Americans from tests marketed with false or unsubstantiated claims.

FDA Approach to Expanding Access to Serology Tests

First, we continue to provide the opportunity for interested developers to request FDA authorization through the emergency use authorization (EUA) process. To date, we have already issued four EUAs for serological tests, and we expect that number to continue to grow in the coming weeks. The FDA encourages developers to submit EUA requests for their tests, as an EUA will provide laboratories and providers with assurance that FDA has reviewed that test. We are working around-the-clock to review EUA submissions quickly and we continue to take steps to ensure the process is as streamlined and efficient as possible. For example, we are working on EUA Templates that laboratories and commercial manufacturers may use to facilitate the preparation and submission of an EUA request. We expect to make them available in the coming days.

To enhance the U.S. Government’s ability to identify well-performing tests and inform FDA recommendations and decision making, we are collaborating with the National Institutes of Health’s National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC) to establish a capability at NIH to evaluate serological tests for developers. This effort includes tests already available for use, as well as tests not yet on the market where additional validation data is needed to support an EUA. Performance assessments for serological tests will begin soon, and we expect to start seeing results shortly thereafter. We will review NIH’s results expeditiously, and performance results from NIH’s assessment may complement and inform the determination of whether FDA issues an EUA for a particular test.

Recognizing that more flexibility was needed during a pandemic of this scale and speed, and incorporating feedback from the medical community, states and test developers, we have also provided regulatory flexibility for serological tests in an effort to provide laboratories and health care providers with early access to these tests with the understanding that the FDA had not reviewed or authorized (or “approved”) them, at least not initially, and these tests should not be used for diagnosing or excluding active SARS-CoV-2 infection. Specifically, last month, as part of our broader strategy, the FDA issued a policy explaining that FDA does not intend to object when developers of serological tests market or use their tests without prior FDA review where: 1) the tests are validated by the developer to determine that they are accurate and reliable, 2) notification of the developer’s validation is provided to FDA, and 3) the tests are labeled appropriately, including that they are not to be used as a sole basis for diagnosis. Our policy does not apply to at-home specimen collection or at-home testing because of the added challenges in assuring test accuracy that these pose. The policy does apply to tests that can be performed in patient care settings. Laboratories could validate tests they receive from commercial manufacturers and determine if they should be used in their facilities. Some laboratories have already done so or have developed their own serological tests.

The bottom line is that FDA still expects tests to be validated even under our revised policy for tests. However, the EUA process or an evaluation by NIH supports greater confidence in test performance.

How the Tests Work

Unlike a test designed to diagnose an active COVID-19 infection (specifically from the SARS-CoV-2 virus), serological tests can help identify individuals who have developed an immune response to the virus, either as part of an active infection or a prior infection. The tests detect the presence of antibodies in the blood – if antibodies are present, that indicates that the person has been exposed to the virus and developed antibodies against it, which may mean that person has at least some immunity to the coronavirus. In the early days of an infection when the body’s immune response is still building, antibodies may not be detected, which is why serological tests should not be used as the sole basis to diagnose or exclude infection with the SARS-CoV-2 virus.

There is still a great deal about COVID-19 immunity that we don’t yet fully understand. For example, we don’t yet know that just because someone has developed antibodies, that they are fully protected from reinfection, or how long any immunity lasts. We do expect that data from more widespread serological testing will help us track the spread of the virus nationwide and assess the impact of our public health efforts now, while also informing our COVID-19 response as we continue to move forward. Determining the next steps in our response to COVID-19 is partially dependent on an accurate assessment of our national efforts thus far, and the quality of data for making this decision is dependent on accurate testing products.

Why Validation Data Are Needed

All clinical tests should be validated prior to use, and this expectation is articulated in our March 16 policy. We have provided regulatory flexibility regarding the independent check by FDA for antibody tests that are limited in their clinical applications, but still expect all developers to validate their tests prior to offering them for limited clinical uses.

To minimize the number of false positive results, serological tests must be well-designed to specifically identify antibodies against SARS-CoV-2 and must not “cross-react,” or provide positive results when encountering antibodies against other respiratory viruses.

Concerns and Education for Frontline Workers and States

Currently, we are working on several fronts to provide more clarity about which tests have received FDA review and which have not. In addition, to facilitate awareness of these serological tests, the FDA has been posting on its website the tests for which it has received a notification under this policy since mid-March. We have also updated our website to better clarify which tests have been authorized by FDA and which have not been authorized. However, some test developers have misused the serology test kit notification list to falsely claim their serological tests are FDA approved or authorized. Others have falsely claimed that their tests can diagnose COVID-19. When we become aware of these issues, we have and will continue to take appropriate action against firms making or distributing unvalidated tests or those making false claims, such as issuing Warning Letters requesting that companies stop their unlawful promotion and detaining and refusing fraudulent test kits at the border.

SOURCE U.S. Food and Drug Administration
http://www.fda.gov

Filed Under: Tech Tagged With: COVID-19, Coronavirus

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

Unfulfilled Dreams: The Aftermath of China’s Stalled Real Estate Developments
Huawei on the Brink: Biden Administration Considers Cutting Off the Tech Giant”
Key Fire Industry Trends for 2023
The Future of Food: Top Trends to Watch in 2023 and Beyond
How to discover the treasure trove of hidden marketing insights by watching customer behavior
Navigating Uncertainty: Prioritizing Hydrogen R&D Efforts for a Sustainable Future
Unleashing the Hidden Talent Pool: The Rise of STARs – Skilled Through Alternative Routes

Market Research Media

Turn Your Story into a Game: The Art of Gamifying Your Plot
The end of cheap money is redrawing the map of corporate earnings
The Future of Virtual Reality: How VR is Changing Industries
Market Research Media Survey: The State of Streaming Services
Media measurement services provide a holistic view of cross-media consumption
Gen Z ranks top in luxury sales
How to market recycled products

Secondary Sidebar

Tech Events

The crypto world is facing a crisis of confidence
ScyllaDB Summit 2023 taking place online on February 15-16, 2023
DLD 2023, an innovation festival, February 1-3, 2023, Tel Aviv, Israel
Cybersecurity Innovations Take Center Stage at Cybertech 2023 in Tel Aviv
Chiplet Summit, January 24-26 2023, the Doubletree by Hilton San Jose Hotel

Venture Capital

The Importance of Diversity and Inclusion in the Workplace
Sequoia Capital announces its $195 Mln dedicated seed fund
Sublime Systems Secures $40 Million Series A to Electrify and Scale Decarbonized Cement Production
actyv.ai Raises Pre-Series A Funding to Fuel Global Expansion, Product Enhancement
Ottopia announces $14.5M Series A Funding Round

Footer

Recent Posts

  • The Rise of Virtual Power Plants: Innovating Energy Management
  • DLD 2023 is coming
  • Barcelona Cybersecurity Congress Has Been a Success
  • The Unstoppable Rise of RISC V Architecture
  • Revolutionizing Education: The Power of Automated Tutoring Lessons
  • Revolutionizing the Fashion Industry: Algae-based Yarns and Dyes Take on Fast Fashion
  • Cybertech 2023 kicks off in Tel Aviv
  • Reducing Waste, Saving Energy: How Water Companies Can Recycle Residual Heat Energy
  • China’s Quest for Indigenized Semiconductor Production: Hurdles and Challenges Ahead
  • Big Tech Layoffs Lead to a Booming Demand for Skilled Workers

App Coding

Cybertech 2023 in Tel Aviv: Navigating the Challenges of App Security
monday.com Adds Built-In Monetization Solution to the apps marketplace
New app to help northeastern Illinois drivers avoid traffic and earn rewards for improving their commute
Code Intelligence raises $12M Series A
NLP techniques are bridging the gap between text documents

API Coding

How to recognize malware API
One AI to Take on Global Language AI Challenge with NLP-as-a-service Platform for Developers
WSO2 Completes $93 Million Series E Growth Funding Round with the Investment from Info Edge
Cybertech 2023 in Tel Aviv: Securing the Future with API Security
What is an API Gateway?

Blockchaining

Join Our Team as a Blockchain Developer - Revolutionize the Future
BSV Blockchain Association sponsors WeAreDevelopers World Congress in Berlin
What are DLT ledgers?
What is Web3?
State of Technology Overview: Blockchaining 2023

Event Calendar

NAHB International Builders’ Show (IBS 2023) in Las Vegas from January 31 to February 2, 2023
India’s largest biennial automobile exhibition Auto Expo 2023 held on January 12-15, 2023 at Pragati Maidan, New Delhi
NRF 2023, Retail’s Big Show and Expo, January 15 to 17, 2023, Jacob K. Javits Center, New York
DOMOTEX Hannover 2023′ in Germany from 12-15 January
Electrify Expo Austin Set to Be Largest EV Demo Event of the 2022 Season, November 12-13, 2022, Austin, Texas

Copyright © 2022 Technologies.org

Media Partners: Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT